This clinical trial was conducted to demonstrate the efficacy and safety of a 91-day extended-regimen, low-dose combination oral contraceptive (OC) consisting of 84 days of ethinyl estradiol (EE) 20 mcg/levonorgestrel (LNG) 100 mcg, followed by 7 days of 10 mcg EE in place of placebo.
A multicenter open-label, single-treatment, Phase 3 study evaluated women aged 18 through 40 years over a treatment period of up to 1 year (four 91-day extended cycles). All subjects completed daily paper diaries to monitor compliance, bleeding and additional forms of contraception used during the course of the study.
A total of 1249 subjects completed the study. The Pearl Index was 2.74 (95% confidence interval, 1.92���3.78), based on 36 pregnancies that occurred after the onset of treatment and within 14 days after the last combination tablet in women aged 18���35 years. Among compliant-use subjects 18���35 years old, the Pearl Index was 1.73 based on 22 on-treatment pregnancies. The life table pregnancy rate for subjects 18���35 years of age was 2.39%. Cycle control and adverse events reported with this regimen were similar to those reported with other low-dose OCs.
This study demonstrated effective prevention of pregnancy with a 20-mcg EE, 91-day extended-regimen OC. In addition, the regimen was well tolerated and incidence of adverse events were consistent with what has been reported with other low-dose OCs.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Contraception
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Trends in the content and use of oral contraceptives in the United States, 1964���88.Am J Public Health. 1991; 81: 90-96
- Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins.Obstet Gynecol. 1993; 81: 1034-1047
- Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.BMJ. 1996; 312: 83-88
- Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study.Lancet. 1995; 346: 1575-1582
- Twenty micrograms vs. >20 mcg estrogen oral contraceptives for contraception: systematic review of randomized controlled trials.Contraception. 2005; 71: 162-169
- Manipulation of human ovarian function: physiological concepts and clinical consequences.Endocr Rev. 1997; 18: 71-106
- Ovarian activity in women taking an oral contraceptive containing 20 mcg ethinyl estradiol and 150 mcg desogestrel: effects of low estrogen doses during the hormone-free interval.Am J Obstet Gynecol. 1998; 179: S18-S24
- Inhibition of ovulation by an oral contraceptive containing 100 micrograms levonorgestrel in combination with 20 micrograms ethinylestradiol.Contraception. 1996; 54: 299-304
- Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression.Am J Obstet Gynecol. 2004; 190: 943-951
- A meta-analysis on the correlation between ovarian activity and the incidence of intermenstrual bleeding during low-dose oral contraceptive use.Gynecol Endocrinol. 2003; 17: 107-114
- Effects on serum hormone levels of low-dose estrogen in place of placebo during the hormone-free interval of an oral contraceptive.Contraception. 2008; 77: 34-39
- Evaluation of pituitary���ovarian axis suppression with three oral contraceptive regimens.Contraception. 2008; 77: 162-170
- Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen.Contraception. 2008; 78: 16-25
- Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone.Contraception. 2004; 70: 191-198
- Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 microg (Loestrin 24 Fe).Contraception. 2007; 75: 16-22
- Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: Phase 3 study results.Contraception. 2006; 74: 439-445
- Current US Prescribing Information.Ortho-McNeil Pharmaceuticals, Inc., New Jersey2004
- Final summary minutes. January 23���24, 2007.Accessed March 20, 2009)
- Body mass index, weight, and oral contraceptive failure risk.Obstet Gynecol. 2005; 105: 46-52
- Body weight and risk of oral contraceptive failure.Obstet Gynecol. 2002; 99: 820-827
- The role of body weight in oral contraceptive failure: results from the 1995 National Survey of Family Growth.Ann Epidemiol. 2005; 15: 492-499
- Obesity and oral contraceptive failure: findings from the 2002 National Survey of Family Growth.Am J of Epidemiol. 2007; 166: 1306-1311
- Body mass index and risk for oral contraceptive failure: a case-cohort study in South Carolina.Ann Epidemiol. 2006; 16: 637-643
- Efficacy, safety and cycle control of five oral contraceptive regimens containing norgestimate and ethinyl estradiol.Contraception. 2003; 67: 431-437
- Endometrial effects of a 91-day extended regimen oral contraceptive with low-dose estrogen in place of placebo.Contraception. 2008; 77: 91-96
Published online: September 04, 2009
Accepted: July 9, 2009
Received in revised form: July 7, 2009
Received: March 20, 2009
���This study was funded by Duramed Pharmaceuticals, Inc. Drs. Reape and Margolis are full-time employees of Duramed Research, Inc.
© 2010 Elsevier Inc. Published by Elsevier Inc. All rights reserved.